BioAtla, Inc. - BCAB STOCK NEWS

BioAtla (NASDAQ: BCAB) reported Q2 2024 financial results and clinical progress. Key highlights include:

1. Ozuriftamab vedotin granted Fast Track Designation by FDA for head and neck cancer; FDA meeting anticipated in 2H 2024.

2. Evalstotug showed low incidence of immune-related adverse events; Phase 2 combination study with pembrolizumab on track for initial data in 2H 2024.

3. Mecbotamab vedotin Phase 2 trial in NSCLC showed improved overall survival in patients with KRAS mutations.

4. Cash balance projected to fund operations through Q3 2025.

5. Q2 2024 financial results: R&D expenses $16.2M (down from $31.0M in Q2 2023), G&A expenses $5.8M, net loss $21.1M, cash and equivalents $61.7M as of June 30, 2024.

BioAtla (Nasdaq: BCAB), a global clinical-stage biotechnology company specializing in Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors, has announced its upcoming second quarter 2024 financial results and business highlights conference call. The event is scheduled for Thursday, August 8, 2024, at 4:30 p.m. ET.

Investors and interested parties can access the webcast through the provided link or join via phone using the dial-in numbers. The financial results press release will be available on the company's website prior to the call. A replay of the conference call will also be accessible through the Investors section of BioAtla's website.

BioAtla (Nasdaq: BCAB) hosted a virtual R&D Day highlighting updates on its clinical programs. Key findings include:

1. Mecbotamab vedotin (CAB-AXL-ADC): Showed clinical benefit in NSCLC patients with mutant KRAS variants. AXL expression ≥1% correlated with clinical benefit in heavily pretreated patients.

2. Evalstotug (CAB-CTLA-4 antibody): Demonstrated promising anti-tumor activity as monotherapy and in combination with PD-1, with a differentiated safety profile and low incidence of immune-related adverse events.

The event featured insights from key opinion leaders Dr. Edwin Yau, Dr. Omid Hamid, and Dr. Ankit Mangla, who shared positive observations on the clinical benefits and safety profiles of BioAtla's therapies.

BioAtla (Nasdaq: BCAB) has received FDA Fast Track Designation for ozuriftamab vedotin (CAB-ROR2-ADC) to treat recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). This conditionally active antibody drug conjugate has shown promising clinical activity and a manageable safety profile in treatment-refractory SCCHN patients during its Phase 2 trial. The company plans to meet with the FDA in the second half of 2024 to discuss a potential registrational trial. Fast Track Designation could expedite development and review, potentially leading to priority review if supported by clinical data at BLA submission.

BioAtla, a global clinical-stage biotechnology company specializing in CAB antibody therapeutics for solid tumors, will host a virtual R&D Day on July 25, 2024, at 10:00 AM ET. This event will provide updates on the company's clinical programs and pipeline. Attendees can register online, and a live Q&A session will follow the presentation.

BioAtla (Nasdaq: BCAB), a clinical-stage biotech firm specializing in Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors, announced its participation in the Jefferies Global Healthcare Conference in New York from June 4-6, 2024.

The event will feature a fireside chat and one-on-one investor meetings on June 5, 2024, at 8:00 a.m. ET. The webcast will be available for interested parties.

BioAtla announced promising Phase 1 clinical trial results for evalstotug, a conditionally active anti-CTLA-4 antibody, in combination with nivolumab.

Key findings include prolonged progression-free survival (PFS) of over 10 months in refractory PD1 failure patients, with manageable safety profiles allowing extended treatment durations.

High doses (up to 1 gram) showed positive responses, including complete and partial responses in various carcinomas. The disease control rate was 52%, and several patients remained progression-free for over a year.

BioAtla plans to commence a Phase 3 trial in late 2024 for first-line metastatic BRAF-mutated melanoma, following an anticipated FDA meeting.

BioAtla (Nasdaq: BCAB) announced its Q1 2024 financial results and clinical progress. Key highlights include positive Phase 2 data for ozuriftamab vedotin in SCCHN, with 11 responses and an 86% Disease Control Rate (DCR). Evalstotug's Phase 1 study shows promising safety and efficacy, with upcoming Phase 2 data readouts. Mecbotamab vedotin's Phase 2 trial in UPS is progressing well. BioAtla also reported a cash balance of $80.6 million, projected to fund operations into 2H 2025. Financial results show a reduction in R&D and G&A expenses but a net loss of $23.2 million, lower than last year's $27.5 million. Management will host a conference call to discuss these updates.

BioAtla, Inc. (Nasdaq: BCAB) will be participating in the Citizens JMP Life Sciences Conference in New York on May 13-14, 2024. The company focuses on developing CAB antibody therapeutics for solid tumor treatment. Management will engage in a fireside chat and investor meetings. This conference provides a platform for BioAtla to showcase its advancements.